![Page 1: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/1.jpg)
Protection of Human SubjectsCase #2
Salim DarwicheJean-Bernard Nobs
Marco PisanoAnders SandholmValentina Triacca
Responsible Conduct in Biomedical Research
![Page 2: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/2.jpg)
Philadelphia, September 13th, 1999
![Page 3: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/3.jpg)
The Father
My Son, Jesse
![Page 4: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/4.jpg)
• Jesse Gelsinger• Born 18th of June 1981• Pretty normal infancy• At ~3 years: first signs of metabolic disorder
Final diagnosis: OTC (Ornithine transcarbamylase
deficency syndrome)
• High level of ammonia in the blood• Mild (6% enzyme efficiency)• Could be controlled by medication and diet
![Page 5: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/5.jpg)
Jesse grew up, having a normal life, but taking nearly 50 pills a day!! He was inconsistently taking them.
• 1998: We were made aware of a clinical trial, in Philly, about OTC.
• Christmas 1998: Heavy crisis.
Jesse’s primary medication was not effective enough, and was not taken constantly.
With the new medicine: great results!! Jesse was ordering and eating food like a teenager!
Jesse – the teenager
![Page 6: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/6.jpg)
• Technique to be used: • injection of viral vector into the liver.
• Danger associated:• 8 hours immobility• Flu-like symptoms for a few days• Remote possibility to contract hepatitis• Most dangerous part: needle biopsy to be performed one
week after the infusion: 1 to 10 000 chance of death.
• Previous results: • Mice: working temporarily – preventing death• Most recent patient: + 50% efficiency!! Wow!!!• After Jesse, they can show exactly how well this works!• Over 500.000 people in the US will benefit from this study
1999 - Clinical trial proposal: Gene Therapy
![Page 7: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/7.jpg)
The Scientist
A Treatment for OTC
![Page 8: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/8.jpg)
Ornithine transcarbamylase (OTC) deficiency
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=ucd-overview&rendertype=figure&id=ucd-overview.F1
![Page 9: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/9.jpg)
Gene therapy
![Page 10: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/10.jpg)
What course of action would your recommend?
![Page 11: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/11.jpg)
The Physician
Morbidity and Mortality
![Page 12: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/12.jpg)
0 10 20 30 40 50 60 70 80 90 100
Clinical Summary
![Page 13: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/13.jpg)
Post-Mortem Evaluation:
-Proximate cause of death was acute respiratory distress syndrome.
-Systemic inflammation complicated by multi-organ failure.
-Cause of systemic inflammatory response syndrome not clear.
- OTC 018 vs. OTC 019
![Page 14: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/14.jpg)
How would you handle the situation?
![Page 15: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/15.jpg)
The Media
The Fallout, The Scandal
![Page 16: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/16.jpg)
FDA investigates on the way UPenn conducted the trial
![Page 17: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/17.jpg)
Dr. Wilson failed to:
• Adequately protect the safety and welfare of subjects, enrolling subjects who were not eligible for the studyEx: Gelsinger’s high ammonia levels should have excluded him from the study
• Adequately protect the rights of subjects disinformation about risks and adverse events that occurred during the study
« How many subjects experienced adverse effects? »Dr. Wilson’s point of view: 0!
![Page 18: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/18.jpg)
• Obtain informed consent1) Side effects experienced by subjects previously involved in the trial: not
mentioned!2) 2 monkeys given a similar treatment died: not mentioned!3) Risk of disseminated intravascular coagulation: not mentioned!4) He didn’t inform subjects about his financial interest (holding 30% of GENOVO)
• Accurately and completely identify changes in the research activities
1) He changed inclusion criteria without informing the competent institution2) He eliminated the exclusion criterion of history of hepatic or vascular disease
![Page 19: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/19.jpg)
Post-hoc Expert Opinion
Don’t give up on gene therapy
![Page 20: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/20.jpg)
Impact on research
• Understand riskNo one should be allowed to sign up for a
experimental drug and treatment if they don’t clearly understand if its safe or not
• Gene therapy and stem cell research– Someone has to go first, this will include risk
• In the US, no national insurance program covering drug experiment.
![Page 21: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/21.jpg)
New treatment
• Researchers studied the immune system• 1 Case, Leber congential amaursis
– Progress loss of vision, lead to blindness• Missing an enzyme (Gene RPE65)• Alessandro Cannata
– 18 years old– Vision problems since birth
![Page 22: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/22.jpg)
Alessandro Cannata
• University of Pennsylvania School of Medicine• A tiny dose of healthy RPE65 gene was inserted
into a “gentle” virus (AAV)• Injected into the retina
– (Retinal cells don’t divide)• Only a phase 1 safety trial
– (small dosage)
![Page 23: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/23.jpg)
Alessandro Cannata
“When I was returning home from Philadelphia and still wore the bandage over my eye, I was at a restaurant and wanted to order but could not see the waiter, so I removed the bandage and it was as if someone had turn on a light”
![Page 24: Protection of Human Subjects Case #2 Salim Darwiche Jean-Bernard Nobs Marco Pisano Anders Sandholm Valentina Triacca Responsible Conduct in Biomedical](https://reader036.vdocuments.mx/reader036/viewer/2022062423/56649f4d5503460f94c6ddde/html5/thumbnails/24.jpg)
Final Comments